Re-challenge Pembrolizumab Study as a Second or Further Line in Patients With Advanced NSCLC
Clinical trial NCT03526887 · COMPLETED
Trial details
- NCT number
- NCT03526887
- Sponsor
- Spanish Lung Cancer Group
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-07-15
- Primary completion
- 2022-12-30
- Enrollment
- 73
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.